Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse

NCT06138483 is registered in ClinicalTrials.gov with Centro di Riferimento Oncologico - Aviano as lead sponsor.

NCT NCT06138483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06138483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Lead sponsor
Centro di Riferimento Oncologico - Aviano
Phase
Observational
Overall status
Unknown status
Start date
April 19, 2019
Completion date
June 30, 2025
Enrollment
267 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal squamous cell carcinoma